Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer
Launched by JAGIELLONIAN UNIVERSITY · Apr 24, 2025
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific surgery called retroperitoneal lymph node dissection (RPLND) affects urinary and sexual functions in men with testicular cancer. RPLND involves removing lymph nodes from the abdomen and is often done when chemotherapy isn't an option or after chemotherapy when some cancer remains. While we know this surgery can impact ejaculation, we want to learn more about how it might also affect urination and erections.
The trial will involve adult men who are planning to have this surgery. Participants will answer questions and take simple tests regarding their urinary and sexual health before the surgery and during follow-up visits for up to six months afterward. To be eligible, men must be adults with testicular cancer who are scheduled for RPLND. Those who have had this surgery before or who do not wish to participate will not be included. Ultimately, the goal is to better understand the effects of this surgery so that doctors can provide better information and care for their patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)
- Exclusion Criteria:
- • History of RPLND
- • Lack of consent
About Jagiellonian University
Jagiellonian University, one of the oldest and most prestigious institutions of higher education in Poland, is a leading sponsor of clinical trials dedicated to advancing medical research and healthcare innovation. With a strong commitment to scientific excellence, the university leverages its extensive resources, multidisciplinary expertise, and collaborative network to conduct rigorous clinical studies that contribute to the development of new therapies and treatment strategies. Jagiellonian University emphasizes ethical research practices and strives to enhance patient outcomes through evidence-based findings, making significant contributions to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Krakow, Malopolska, Poland
Patients applied
Trial Officials
Anna K. Czech, M.D.
Principal Investigator
Jagiellonian University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported